Rubicon Research
Rubicon Research Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
The company remains confident in a strong growth trajectory with broad-based revenue growth across both new launches and existing products. Rubicon Research remains confident in maintaining a strong growth trajectory into FY ‘27 and ‘28, though specific guidance is not provided.
From Rubicon Research's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company remains confident in a strong growth trajectory with broad-based revenue growth across both new launches and existing products.
- Specialty portfolio contribution to gross profit has increased from around 27% to about 31-32%, and is expected to continue growing.
- R&D productivity has improved (from 3.3x to 5.7x revenue multiple over R&D spend), supporting sustainable incremental revenue growth.
- Demand environment continues to be strong, with no significant dependency on a single product, indicating diversified growth sources.
- The ramp-up of the Pithampur manufacturing facility in CY 2026 - early CY 2027 is expected to aid capacity, supporting revenue growth.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Rubicon Research said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company acquired the Pithampur manufacturing facility in June 2025 to build more capacity and capabilities, including high potent oncology, hormones, and steroids, with room for expansion.
- Pithampur is on track for operationalization and validation completion by mid-2026 and expected commercialization by Q1 CY 2027.
- Additional capex of around INR 70 crores was made alongside the Pithampur acquisition.
- The company holds a cash reserve of INR 334 crores, providing "dry powder" for inorganic growth aspirations.
- Evaluations and tactical measures regarding own manufacturing versus outsourcing to optimize margins are ongoing.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Rubicon Research said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Rubicon Research — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹476 Cr, net profit ₹73 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Rubicon Research's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- RPG Life Sciences Ltd (Q3 FY26)
180.0 crore, up from Rs. Key concall takeaways from RPG Life Sciences Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
- SMS Pharmaceuticals Ltd (Q3 FY26)
Q3FY26 Revenue from Operations: ₹210.45 crore, up 21% YoY (from ₹173.35 crore in Q3FY25) [Page 27] . Key concall takeaways from SMS Pharmaceuticals Ltd's Q3…
- Morepen Laboratories Ltd (Q3 FY26)
488 crores, up 17% from Q3 FY25 Rs. Key concall takeaways from Morepen Laboratories Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
- Jubilant Pharmova Ltd (Q3 FY26)
2,143 Cr., up from Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
Frequently Asked Questions
What were Rubicon Research Q3 FY26 results?
The company remains confident in a strong growth trajectory with broad-based revenue growth across both new launches and existing products. Rubicon Research remains confident in maintaining a strong growth trajectory into FY ‘27 and ‘28, though specific guidance is not provided.
What is Rubicon Research share price analysis?
Rubicon Research currently shows a neutral. The stock trades at a P/E of 99.0 with a market cap of ₹28,549 Cr. Investors should review the full earnings analysis for detailed insights.
Is Rubicon Research planning capital expenditure?
The company acquired the Pithampur manufacturing facility in June 2025 to build more capacity and capabilities, including high potent oncology, hormones, and steroids, with room for expansion.
Keep Rubicon Research on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.